Trial Profile
Phase I Trial of the Combination of Bortezomib and Clofarabine in Adults With Refractory Solid Tumors, Lymphomas, or Myelodysplastic Syndromes
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 23 Apr 2024
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Clofarabine (Primary)
- Indications Adenocarcinoma; Cholangiocarcinoma; Colorectal cancer; Lymphoma; Myelodysplastic syndromes; Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- 27 Dec 2023 Planned primary completion date changed from 15 Dec 2023 to 15 Dec 2024.
- 21 Dec 2023 Planned End Date changed from 15 Dec 2023 to 15 Dec 2024.
- 08 Nov 2022 Planned End Date changed from 2 Jun 2023 to 15 Dec 2023.